Search

The circulation of SARS-CoV-2 in endemic regions of dengue fever and its confluence with DENV has been a reason for study. The objective of this study was to determine the epidemiological characteristics of the simultaneous circulation of both viruses in an endemic region and estimate the prevalence of SARS-CoV-2 in patients with dengue infection. A retrospective search of epidemiological databases of both diseases was performed. The records in both databases were classified as Co-infection and reinfection, non-simultaneous infection, and initial dengue diagnosis. The estimated prevalence of SARS-CoV-2 infection in individuals with dengue was 2%. No significant differences were observed in relation to the frequency of symptoms in patients with co-infection versus those with SARS-CoV-2 infection. SARS-CoV-2 was more frequent in non-simultaneous infections as a first infection followed by dengue acquired during the COVID-19 lockdown. Co-infections with both viruses occur in populations from dengue-endemic regions. Due to the similarity of symptoms during the first days of infection, it is important to study the clinical and epidemiological characteristics to reach an opportune diagnosis.

INTRODUCTION: Chagas disease is considered the most serious parasitosis in America, forgotten and neglected in the world, with a characteristic that has its maximum expression in the difficulties and limitations for its diagnosis and treatment. OBJECTIVE: To assess the status of seropositivity of Chagas disease in Mexico, in addition to monitoring the effectiveness of treatment in infected patients. MATERIAL AND METHODS: Systematic reviews were conducted, with searches in Crossref, Google Scholar, Scielo, PubMed and the inclusion of guides and manuals of related health programs was evaluated based on their titles, news and relevance. RESULTS: for seropositivity, the data coincide with 100% in the characterization of the risk factors, as well as in the evaluations in the Blood Transfusion Centers of the country, finding captive cases in each state that explain the persistence of the disease . When monitoring treatments and evidence of effectiveness, the following difficulties arise: prolonged duration and side effects, adding the lack of reliable healing criteria, with an effectiveness of 60-75% in acute cases and in 100% of acute congenital cases, and in chronic cases a variation of between 15 and 30 years was found. CONCLUSIONS: Although the achievements have been commendable in reducing rates, the territory has factors that allow the redistribution of the infection, the evidence on the effectiveness is scarce, there is no evidence of epidemiological follow-up of cases in Mexico with respect to healing indicator.